Researchers have applied a novel high‑resolution gene splicing analysis to a large set of tumour biopsies, revealing hundreds of previously unrecognised potential cancer targets across multiple cancer types.
The study, published in Nature Communications, involved a splicing quantification method developed through collaboration between the Centre for Genomic Regulation in Barcelona, Spain, and Columbia University, New York. This approach differs from traditional analyses by directly measuring RNA splicing events in tumour samples rather than focusing solely on gene mutations.
According to the report, many of the newly identified splicing‑derived targets are active across diverse tumour types, suggesting potential for broad applications in precision oncology. Continued research is expected to explore how these targets might be exploited to develop new cancer therapies.
Inside Precision Medicine has more information.